Latest Pharma News Update... Aug 31
This approval follows a priority review designation by the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) and marks the first ... Jun 23
Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options... May 08
Poziotonib was also presented at European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021 ... Mar 15
In 2018, the FDA approved LORBRENA for the treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least ... Mar 05
XALKORI is the first biomarker-driven therapy for relapsed or refractory ALCL in young people ... Jan 15
New option extends dosing from two to four weeks, reducing medical visits and improving patient convenience ... Jan 15
LORBRENA is a third-generation ALK inhibitor specifically developed to inhibit the most common tumour mutations that drive resistance to current medications and to address ... Dec 29
Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%... Dec 21
Amgen today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for sotorasib, an investigational KRASG12C ... Dec 17
This new dosing option is consistent with the approved Imfinzi dosing in extensive-stage small cell lung cancer and once approved, will be available to ... Dec 15
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations... Dec 03
... Nov 19
European Commission decision marks the first time a dual immunotherapy with limited chemotherapy is approved for patients with non-small cell lung cancer in the ... Nov 09
This acquisition is well positioned to achieve its maximum potential to benefit appropriate cancer patients in need... Nov 06
Libtayo is indicated for advanced non-smal cell cancer with PD-L1 Expression of ≥50%... Oct 31
Roche receives FDA approval for the cobas EGFR mutation test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with ... Oct 30
Galera Therapeutics announces dosing of first patient in the phase 1/2 GRECO-1 clinical trial of GC4711 in combination with SBRT for non-small ... Oct 23
WindMIL Therapeutics and Stephenson Cancer Center announce collaboration to collect bone marrow from patients with renal and urothelial carcinomas ... Oct 14
Opdivo + Yervoy is the first new systemic therapy in over 15 years to be approved by the FDA ... Oct 03
Pfizer Inc. today announced that the U.S. FDA has accepted and granted priority review to the Company’s supplemental New Drug Application for XALKORI ... Sep 23
Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung ... Sep 21
Gavreto is used in treatment of adults with metastatic RET fusion-positive non-small cell lung cancer... Sep 08
GAVRETO, the only once-daily RET-targeted therapy, demonstrated durable efficacy, with complete responses in a subset of patients ... Sep 05
After Japan, EU approves AstraZeneca Imfinzi , along with chemotherapy it could treat small cell lung cancer... Sep 02
-Advertisements-
Monday, May 20, 2024
.jpg)
